Oral Mucositis Market – Overview
Oral mucositis is defined as a disorder that causes the growth of painful lesions of the mucus membranes in the mouth of an individual. Market Research Future (MRFR) has published and released a research report about the global oral mucositis market that adumbrates success for this market at 7% CAGR (Compound Annual Growth Rate) during the forecast period between 2017 and 2023.
The rising incidence of cancer is the prime driver for the global oral mucositis market. The widespread use of chemotherapy, due to the absence of feasible alternatives, is also a contributing factor to the growth of the global oral mucositis market.
Observing the market structure, this report offers insights about factors affecting the market growth. Measuring the market size and foretelling the revenue, this reports examines and monitors the competitive developments of market players that include joint ventures, new product developments, mergers and acquisitions, research and developments (R&D), and strategic alliances.
The key factors spurring the growth of the global oral mucositis market include the growing relevance of the growing prevalence of oral cancer, advanced medical facilities, the growing demand for cancer treatment facilities, and side effects treatment.
GET FREE SAMPLE COPY OF “Oral Mucositis Market Research Report- Global Forecast To 2023” @ https://www.marketresearchfuture.com/sample_request/1531
Leading Key Players
The key players in the global oral mucositis market are
AMAG Pharmaceuticals Inc. (USA)
Izun Pharmaceutical Ltd (USA)
Kinnear Pharmaceuticals (USA)
Shoreline Pharmaceuticals Inc. (USA)
Soligenix Inc. (USA)
Oral Mucositis Market – Segmentation
The global oral mucositis market is segmented on the basis of cause and end use.By cause, the oral mucositis market is segmented into chemotherapy, radiotherapy, and hematopoietic stem cell transplantation. Chemotherapy is the leading cause of oral mucositis and is likely to remain the same over the forecast period.
By end user, the hospitals and oncology hospitals segments dominate the global oral mucositis market due to its close association with cancer. Other end users include dental clinics and research institutes.
Detailed Regional Analysis
The global oral mucositis market has been segmented into the regional markets known as The Americas (North America & South America), Asia Pacific, Europe and the Middle East & Africa (MEA). The Americas is the largest regional market.
In North America, the market for oral mucositis is mainly driven by the branded drugs. Due to technological advancement and the availability of advanced medical facilities, North America is the bigger market over South America
In North America, the USA and Canada are the biggest country-specific markets. In South America, Argentina and Brazil are two strong economies that have the potential to grow as suitable markets.
In the European region, the incidences of anal cancer are less than the incidence rate in the Americas. However, in terms of technological advancement and the availability of advanced medical facilities, Europe is second only to North America. Therefore, compared to the Americas, Europe is the smaller but very significant regional market.
OBTAIN PREMIUM RESEARCH REPORT DETAILS @ https://www.marketresearchfuture.com/reports/oral-mucositis-market-1531
The critical country-specific markets in this region are France, Germany, Italy, Spain, and the UK, followed by the remaining countries of Europe
The Asia Pacific region is growing is expected to grow as a market by average rate due to the growing life expectancy in this region. Hospitals with advanced medical facilities are steadily growing in this region. In this region, the key country-specific markets are India, China, Japan, and South Korea, followed by remaining countries of the Asia Pacific region.
As a market, MEA region is experiencing very slow growth. The slow market growth and MEA region having a low share in the global market is due to due to poor countries, lack of awareness, lack of advanced medical facilities, low standard of medical facilities, lack of education, lack of healthcare facilities, and majority governments not considering healthcare a priority.
Latest Industry News
- Innovation Pharmaceuticals, a clinical-stage pharmaceutical company, has received a new patent allocated to its defensin-mimetic drug, known as Brilacidin. Brilacidin has been successfully evaluated in clinical trials in oral mucositis, inflammatory bowel disease, and serious skin infections, with planned extension into dermatological diseases. 2 JAN 2019
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar